Outcome of Reverse Switching From CT-P13 to Originator Infliximab in Patients With Inflammatory Bowel Disease. Mahmmod S, Schultheiss JPD, van Bodegraven AA, Dijkstra G, et al. Inflamm Bowel Dis 2021 Feb 4. pii: 6128461. doi: 10.1093.

Read + Share

Amedeo Smart

Independent Medical Education

Mahmmod S, Schultheiss JPD, van Bodegraven AA, Dijkstra G, et al. Outcome of Reverse Switching From CT-P13 to Originator Infliximab in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis 2021 Feb 4. pii: 6128461. doi: 10.1093.
PMID: 33538298